Author

Fiorella Cañete

CLINICAL AND PHARMACOKINETIC IMPACT OF METHYLPREDNISOLONE PREMEDICATION WITHDRAWAL IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE THERAPY WITH INFLIXIMAB
CLINICAL AND PHARMACOKINETIC IMPACT OF METHYLPREDNISOLONE PREMEDICATION WITHDRAWAL IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE THERAPY WITH INFLIXIMAB

MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY
MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY

Fiorella Cañete  et al.

CLINICAL AND PHARMACOKINETIC IMPACT OF METHYLPREDNISOLONE PREMEDICATION WITHDRAWAL IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE THERAPY WITH INFLIXIMAB
CLINICAL AND PHARMACOKINETIC IMPACT OF METHYLPREDNISOLONE PREMEDICATION WITHDRAWAL IN INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE THERAPY WITH INFLIXIMAB

Fiorella Cañete  et al.

MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY
MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY

CAN HOSPITAL ADMISSIONS FOR LOWER GASTROINTESTINAL BLEEDING BE REDUCED? IMPLEMENTATION OF TWO SCALES FOR THE PREDICTION OF SAFETY DISCHARGE IN A RETROSPECTIVE COHORT
CAN HOSPITAL ADMISSIONS FOR LOWER GASTROINTESTINAL BLEEDING BE REDUCED? IMPLEMENTATION OF TWO SCALES FOR THE PREDICTION OF SAFETY DISCHARGE IN A RETROSPECTIVE COHORT

Fiorella Cañete  et al.

MANAGEMENT AND OUTCOMES OF LOWER GASTROINTESTINAL BLEEDING IN PATIENTS ON ANTICOAGULATION
MANAGEMENT AND OUTCOMES OF LOWER GASTROINTESTINAL BLEEDING IN PATIENTS ON ANTICOAGULATION

Fiorella Cañete  et al.

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

Fiorella Cañete  et al.

IMMUNOSUPPRESSIVE TREATMENT IS NOT A RISK FACTOR TO DEVELOP A WORSE SARS-COV-2 INFECTION IN ELDERLY IBD PATIENTS. AN OBSERVATIONAL, DESCRIPTIVE, COHORT STUDY
IMMUNOSUPPRESSIVE TREATMENT IS NOT A RISK FACTOR TO DEVELOP A WORSE SARS-COV-2 INFECTION IN ELDERLY IBD PATIENTS. AN OBSERVATIONAL, DESCRIPTIVE, COHORT STUDY

Fiorella Cañete  et al.

CHARACTERIZATION OF THE FATTY ACID PROFILE OF THE CREEPING FAT OF CROHN’S DISEASE IN COMPARISON TO INFLAMMATORY BOWEL DISEASE-FREE CONTROLS
CHARACTERIZATION OF THE FATTY ACID PROFILE OF THE CREEPING FAT OF CROHN’S DISEASE IN COMPARISON TO INFLAMMATORY BOWEL DISEASE-FREE CONTROLS

Fiorella Cañete  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Fiorella Cañete  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

Fiorella Cañete  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Fiorella Cañete  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Fiorella Cañete  et al.

Item 1 - 13 / 13
1